As depicted in Figure 5, several active substances have been demonstrated to inhibit ferroptosis and ameliorate the symptoms of obesity-related chronic metabolic diseases by means of removing excess iron, neutralizing lipid peroxides and activating pathways such as the NRF2 signal. Here, NFE2L2 is linked to obesity due to melanocortin 4 receptor deficiency.